<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092556</url>
  </required_header>
  <id_info>
    <org_study_id>2018-10-010-002</org_study_id>
    <nct_id>NCT04092556</nct_id>
  </id_info>
  <brief_title>tDCS for Multiple System Atrophy With Cerebellar Feature</brief_title>
  <official_title>Exploratory Study to Evaluate the Effective Site for Control of Motor Coordination Function After Transcranial Direct Current Stimulation in Multiple Systemic Atrophy With Cerebellar Feature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to investigate most effective site for control the motor coordination
      using transcranial direct current stimulation in multiple system atrophy with cerebellar
      feature
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants receive transcranial direct current stimulation (tDCS) over M1, cerebellar
      cortex or sham stimulation for 30 minutes. The type of stimulation depends on random
      assignment. The participants have a 1 week of wash out period between each stimulation.

      The assessment will be done by International Cooperative Ataxia Rating Scale (ICARS),
      GAITRITE (CIR Systems Inc., Clifton, New Jersey, USA) and PEDOSCAN (DIERS PEDO, Germany) at
      baseline and immediately after each treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from International Cooperative Ataxia Rating Scale (ICARS)</measure>
    <time_frame>per session: at baseline and within 30 minutes tDCS treatment completion</time_frame>
    <description>The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from temporospatial parameters of gait</measure>
    <time_frame>per session: at baseline and within 30 minutes tDCS treatment completion</time_frame>
    <description>Gait parameters measured by GAITRite system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from posturography</measure>
    <time_frame>per session: at baseline and within 30 minutes tDCS treatment completion</time_frame>
    <description>Posturography measured by Pedoscan system</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple System Atrophy, Cerebellar Variant (Disorder)</condition>
  <arm_group>
    <arm_group_label>tDCS (M1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will be submit to tDCS applied over the motor cortex (M1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS (Cerebellar cortex)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will be submit to tDCS applied over the cerebellar cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The participants will be submit to sham stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation</intervention_name>
    <description>tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.</description>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_label>tDCS (Cerebellar cortex)</arm_group_label>
    <arm_group_label>tDCS (M1)</arm_group_label>
    <other_name>tDCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients who meet the clinical criteria for probable multiple system atrophy with
             cerebellar features (MDS second consensus statement on the diagnosis of multiple
             system atrophy)

          -  2. Patients aged between 40 and 70

          -  3. Patients who do not have rigidity and bradykinesia

          -  4. Patients who have given voluntary consent after understanding the content of the
             clinical trial

        Exclusion Criteria:

          -  1. Patients with a serious cognitive disorder, behavioral disorder, or mental illness

          -  2. Patients have history of seizure, stroke, encephalitis, other degenerative
             neurological disease

          -  3. Patients with a serious medical disease

               -  Patients who concomitantly suffer from severe renal impairment, convulsions,
                  stomach ulcers, moderate or more severe liver disease

               -  Patients with un-controlled high blood pressure or diabetes

          -  4. Patients who have taken another investigational products within 4 weeks prior to
             being enrolled in this clinical trial, or patients who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinyoung Youn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinyoung Youn</last_name>
    <phone>82-2-3410-0245</phone>
    <email>genian@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong Hyeon Ahn</last_name>
    <phone>82-2-3410-0245</phone>
    <email>jonghyeon.ahn@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinyoung Youn</last_name>
      <phone>82-2-3410-0245</phone>
      <email>genian@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jinyoung Youn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Cerebellar Ataxia</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

